New immune therapy targets advanced prostate cancer in early trial

NCT ID NCT07192614

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new experimental drug called AZD6621 for men with metastatic prostate cancer that has stopped responding to standard treatments. The research will first find safe dose levels in a small group, then test those doses in more participants to see if the drug helps control the cancer. The drug works by directing the body's immune cells to attack cancer cells that have a specific marker called STEAP2.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Orlando, Florida, 32809, United States
Research Site
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States
Research Site
WITHDRAWN

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

Grand Rapids, Michigan, 49546, United States
Research Site
NOT_YET_RECRUITING

Commack, New York, 11725, United States
Research Site
RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
NOT_YET_RECRUITING

Ghent, 9000, Belgium
Research Site
NOT_YET_RECRUITING

Beijing, 100142, China
Research Site
SUSPENDED

Guangzhou, 510060, China
Research Site
NOT_YET_RECRUITING

Nanjing, 2100008, China
Research Site
NOT_YET_RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Hirakata-shi, 573-1191, Japan
Research Site
NOT_YET_RECRUITING

Kashiwa, 277-8577, Japan
Research Site
NOT_YET_RECRUITING

Amsterdam, 1066CX, Netherlands
Research Site
NOT_YET_RECRUITING

Maastricht, 6229 HX, Netherlands
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 5505, South Korea
Research Site
NOT_YET_RECRUITING

Cambridge, CB2 0QQ, United Kingdom

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER